Goldman Sachs Raises Stake in Olema Pharmaceuticals, Inc. (OLMA)

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is among the best fast money stocks to buy now. During the first quarter, Goldman Sachs Group Inc. expanded its holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 93.6%. Following the purchase of 358,412 shares, the leading bank now owns 741,329 shares of the company’s stock, translating to an investment of $2,787,000 and an ownership of nearly 1.08%.

Oppenheimer is among the many research firms bullish on Olema Pharmaceuticals, Inc. (NASDAQ:OLMA). After the company’s collaboration with Pfizer, aiming to test Pfizer’s next-generation CDK4-selective drug atirmociclib in combination with Olema’s palazestrant, the research firm issued an ‘Outperform’ rating on the stock, along with a price target of $22.

This potential upside of over 130% is no accident, as many believe Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is strategically well-positioned with two key players in HR-positive breast cancer, with the company’s current palazestrant and ribociclib combination study with Novartis.

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) is a California-based clinical-stage biopharmaceutical company developing and commercializing therapies for women’s cancers. Incorporated in 2006, the company is dedicated to impacting breast cancer.

While we acknowledge the potential of OLMA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.